NewTimeSpace News: ESTUN (02715.HK) announced that the Company convened an employee representative congress on 9 July 2026. Mr Zhou Ailin was unanimously elected as employee representative director of the 6th Board of Directors via democratic election.
NewTimeSpace News: SIMCERE PHARMA (02096.HK) announced on 9 July that its Class 1 innovative drug Xibi Xin® (Edaravone and Dexborneol Concentrated Solution for Injection) has been included in the 2026 National Essential Medicines List for the treatment of acute ischaemic stroke. Already listed in national medical insurance, it is the sole neuroprotective agent recommended with Class IIa evidence in Chinese clinical guidelines and has benefited over 6 million AIS patients. The inclusion will accelerate penetration into grassroots medical markets.
NewTimeSpace News: The Hong Kong Stock Exchange (HKEX) issued a disciplinary statement on 9 July imposing reprimands and training orders on EVER REACH GP (03616.HK), four directors and five senior executives. The case stemmed from a RMB320 million circular fund arrangement, which delayed audit procedures and triggered trading suspension. The Company published all overdue financial results in July 2025 and resumed trading in September 2025. Relevant individuals are required to complete 21 hours of compliance training.
NewTimeSpace News: Tat Hong Equipment Service Co., Ltd. (02153.HK) announced on 9 July its 10th issuance of digital securities commercial paper (3-month SGD Series 010) carrying an annual interest rate of 4.40% with a tenor of approximately three months. The Group plans to raise SGD30 million to SGD35 million for working capital requirements. The instruments are issued as security tokens on the SDAX platform under its multi-currency CP programme.
NewTimeSpace News: Dongjiang Environmental Company Limited (00895.HK) announced on 9 July that its subsidiary Guangdong Daxiang Logistics Technology Co., Ltd. was awarded a steel road transportation contract with Zhongnan Steel valued at roughly RMB18.49 million. The contract term expires on 30 June 2027. The connected transaction has been approved by the Board. The Group also disclosed that Daxiang Logistics failed another tender for similar transportation services previously.
NewTimeSpace News: TCL Electronics announced on 9 July that it estimates its revenue for the first half of 2026 will range from HK$60.3 billion to HK$65.7 billion, representing a year-on-year growth of roughly 10% to 20%. Adjusted net profit attributable to parent is projected to hit HK$1.48 billion to HK$1.65 billion, up approximately 40% to 56% year on year.
NewTimeSpace News: Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) announced that the Phase III clinical trial (CTR20261818) of self-developed first-in-class multi-target tumour immune modulator C019199 tablets has officially been initiated for osteosarcoma patients who failed at least two prior lines of treatment. Approximately 120 subjects are planned to be recruited across multiple clinical centres nationwide.
The launch of WebRetriever forms a technical matrix alongside Mano-P, Cider, and Octo. In the first half of 2026, Mininglamp Technology (2718.HK) open-sourced Mano-P, an on-device GUI model (ranking first globally on the dedicated OSWorld model leaderboard), Cider, an inference acceleration framework, and Octo, an Agent collaboration platform. The addition of WebRetriever allows the company to form a complete technical closed loop across four dimensions: "on-device model—inference acceleration—collaboration platform—evaluation standard."
SIMPLICITY HLDG (08367.HK) plans to issue up to 16.56 million shares by placement, with estimated net proceeds of HKD 2.48 million.
NewTimeSpace.com reports, Fenbi Ltd. founder Zhang Xiaolong has resigned as executive director, CEO and chairman due to personal affairs, effective 8 July 2026. Vice president Sheng Haiyan has been appointed to succeed in all these roles and also serves as authorized representative and nomination committee chair. The board considers the combined CEO and chairman role beneficial for leadership consistency, and the resignation does not affect the acting-in-concert arrangement.
By the close of trading on Jul 8, 2026, HUAQIN(03296.HK) saw a gain of 18.81% in its share price, closing at HKD 68.85. During the session, it reached an intraday high of HKD 69.5 and touched an intraday low of HKD 60.65.
By the close of trading on Jul 8, 2026, MINIMAX-W(00100.HK) saw a gain of 11.98% in its share price, closing at HKD 362.6. During the session, it reached an intraday high of HKD 389.8 and touched an intraday low of HKD 311.
NewTimeSpace (newtimespace.com) reported that on July 8, 2026, the chip theme strengthened, with SMIC (00981.HK) surging in volatile trading. As of 13:34, the stock was quoted at HKD 77.550, up 5.58%.
NewTimeSpace (newtimespace.com) News, On July 8, 2026, Hong Kong tech-themed stocks rose strongly in the morning session. As of 09:52, the China Universal CSI HK Equities Information Technology Integration ETF (526030) increased by 1.36%, with the latest price standing at RMB 0.9.In terms of liquidity,China Universal CSI HK Equities Information Technology Integration ETF recorded an intraday turnover rate of 4.21%, with a trading volume of RMB 6.0854 million. Looking at a longer timeframe, as of July 7, the daily average trading volume ofChina Universal CSI HK Equities Information Technology Integration ETF over the past year reached RMB 34.1912 million.
NewTimeSpace News: Chiho Environmental Group Limited (00976.HK) announced on 7 July that it has commenced legal proceedings in the High Court of Hong Kong, seeking a declaration that the appointments of receivers over its subsidiary shares are null and void and an injunction restraining the receivers from taking any actions. The Group has held the view that the receivership appointments were invalid, yet the receivers proceeded to enter into a sale agreement for the Scholz Group. The Company’s shares have been suspended from trading since 1 April 2025 and will remain suspended until further notice.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced that its subsidiary Chia Tai Tianqing entered into an exclusive licensing agreement with AstraZeneca for TQC3721, an in-house developed PDE3/4 inhibitor. The Group will receive an upfront payment of USD200 million, aggregate development, regulatory and sales milestone payments of up to USD1.9 billion, plus tiered royalties at rates up to double digits based on annual net sales.
